SUPERPOTENT CALCITONIN ANALOGS HAVING GREATLY INCREASED HYPOCALCEMIC ACTION IN VIVO

摘要

Superpotent calcitonin analogs (Ct) having greatly increased hypocalcemic action in vivo. The invention relates to calcitonins and calcitonin derivatives such as are employed for the therapy, for example, of osteoporosis, of Paget's disease or of hypercalcemia. The calcitonins and calcitonin derivatives according to the invention are distinguished by a bridging of the amino acids present in the positions 17 and 21. In this case, by means of suitable choice of the amino acids present in these positions an 18-membered or 19-membered ring is produced. This ring leads to an increased conformational stability and to an increased activity of the modified calcitonin. A particularly suitable hCt (human Ct) analog is the type cyclo17.21-[Asp17,Om21]-hCt according to the invention having a 19-membered ring structure between the lactam--bridged Asp17 and Om21.